 Aloka Patel
Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 23 | 2019 | 129 | 8.580 |
Why?
| | Infant, Very Low Birth Weight | 21 | 2019 | 137 | 6.780 |
Why?
| | Breast Feeding | 15 | 2019 | 110 | 5.120 |
Why?
| | Intensive Care Units, Neonatal | 24 | 2018 | 170 | 5.040 |
Why?
| | Infant, Premature | 26 | 2018 | 187 | 4.440 |
Why?
| | Mothers | 10 | 2018 | 123 | 3.970 |
Why?
| | Infant, Newborn | 37 | 2019 | 620 | 3.200 |
Why?
| | Lactation | 8 | 2018 | 65 | 3.030 |
Why?
| | Enterocolitis, Necrotizing | 9 | 2017 | 27 | 2.800 |
Why?
| | Patient Discharge | 5 | 2018 | 99 | 2.300 |
Why?
| | Milk Banks | 5 | 2019 | 20 | 2.160 |
Why?
| | Child Development | 5 | 2019 | 67 | 1.980 |
Why?
| | Infant, Premature, Diseases | 3 | 2017 | 23 | 1.470 |
Why?
| | Intensive Care, Neonatal | 5 | 2019 | 31 | 1.450 |
Why?
| | Breast Milk Expression | 8 | 2018 | 43 | 1.330 |
Why?
| | Infant Nutritional Physiological Phenomena | 7 | 2018 | 46 | 1.280 |
Why?
| | Goals | 3 | 2017 | 45 | 1.150 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2016 | 14 | 1.090 |
Why?
| | Infant | 11 | 2018 | 569 | 1.020 |
Why?
| | Gestational Age | 10 | 2018 | 85 | 1.010 |
Why?
| | Infant Care | 3 | 2016 | 22 | 0.980 |
Why?
| | Infant Formula | 2 | 2019 | 16 | 0.970 |
Why?
| | Continental Population Groups | 3 | 2016 | 94 | 0.960 |
Why?
| | Enteral Nutrition | 2 | 2017 | 49 | 0.950 |
Why?
| | Health Care Costs | 3 | 2016 | 70 | 0.930 |
Why?
| | Female | 32 | 2019 | 14865 | 0.930 |
Why?
| | Social Support | 2 | 2017 | 184 | 0.890 |
Why?
| | Humans | 41 | 2019 | 25163 | 0.880 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2017 | 189 | 0.850 |
Why?
| | Nervous System | 1 | 2017 | 13 | 0.840 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 16 | 0.830 |
Why?
| | Pregnancy in Adolescence | 1 | 2017 | 9 | 0.820 |
Why?
| | Prospective Studies | 10 | 2017 | 1439 | 0.820 |
Why?
| | Maternal Behavior | 1 | 2017 | 14 | 0.820 |
Why?
| | Quality of Health Care | 1 | 2017 | 118 | 0.740 |
Why?
| | Informed Consent | 1 | 2015 | 24 | 0.740 |
Why?
| | Bacteria | 1 | 2016 | 62 | 0.730 |
Why?
| | Quality Improvement | 1 | 2017 | 127 | 0.720 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 49 | 0.720 |
Why?
| | Mother-Child Relations | 1 | 2015 | 38 | 0.720 |
Why?
| | Sepsis | 2 | 2017 | 136 | 0.710 |
Why?
| | Birth Weight | 5 | 2017 | 41 | 0.690 |
Why?
| | Hospitalization | 3 | 2016 | 247 | 0.690 |
Why?
| | Residence Characteristics | 1 | 2016 | 190 | 0.680 |
Why?
| | Male | 25 | 2019 | 14575 | 0.660 |
Why?
| | Decision Making | 1 | 2015 | 172 | 0.650 |
Why?
| | Educational Status | 4 | 2018 | 223 | 0.590 |
Why?
| | Oxygen | 2 | 2003 | 77 | 0.570 |
Why?
| | Pregnancy | 3 | 2017 | 318 | 0.550 |
Why?
| | Sleep | 2 | 2003 | 272 | 0.460 |
Why?
| | Infant, Extremely Low Birth Weight | 3 | 2017 | 20 | 0.460 |
Why?
| | Models, Biological | 2 | 2009 | 417 | 0.400 |
Why?
| | Adult | 9 | 2018 | 8206 | 0.400 |
Why?
| | Child Language | 2 | 2017 | 16 | 0.400 |
Why?
| | Qualitative Research | 2 | 2017 | 90 | 0.380 |
Why?
| | Bottle Feeding | 2 | 2016 | 20 | 0.370 |
Why?
| | Anthropometry | 1 | 2005 | 56 | 0.370 |
Why?
| | Bedding and Linens | 2 | 2003 | 5 | 0.370 |
Why?
| | Carbon Dioxide | 2 | 2003 | 14 | 0.360 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 313 | 0.360 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2017 | 295 | 0.330 |
Why?
| | Retrospective Studies | 6 | 2019 | 2502 | 0.320 |
Why?
| | Prone Position | 1 | 2003 | 10 | 0.310 |
Why?
| | Risk Factors | 4 | 2017 | 2147 | 0.310 |
Why?
| | Motor Activity | 2 | 2017 | 360 | 0.300 |
Why?
| | Incidence | 5 | 2017 | 670 | 0.280 |
Why?
| | Cohort Studies | 5 | 2019 | 1504 | 0.280 |
Why?
| | Respiration | 1 | 2001 | 31 | 0.280 |
Why?
| | Evidence-Based Practice | 3 | 2017 | 71 | 0.280 |
Why?
| | United States | 3 | 2017 | 1946 | 0.270 |
Why?
| | Tissue and Organ Procurement | 2 | 2017 | 30 | 0.250 |
Why?
| | Linear Models | 2 | 2017 | 253 | 0.240 |
Why?
| | Cognition | 2 | 2017 | 848 | 0.230 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 330 | 0.230 |
Why?
| | Multivariate Analysis | 2 | 2017 | 347 | 0.230 |
Why?
| | European Continental Ancestry Group | 3 | 2018 | 518 | 0.220 |
Why?
| | Logistic Models | 2 | 2017 | 434 | 0.220 |
Why?
| | Chicago | 3 | 2016 | 763 | 0.220 |
Why?
| | Nod1 Signaling Adaptor Protein | 1 | 2017 | 1 | 0.210 |
Why?
| | Histamine H2 Antagonists | 1 | 2017 | 8 | 0.210 |
Why?
| | Protective Factors | 1 | 2017 | 13 | 0.210 |
Why?
| | Directive Counseling | 1 | 2017 | 10 | 0.210 |
Why?
| | Nutritive Value | 1 | 2017 | 27 | 0.210 |
Why?
| | Oligosaccharides | 1 | 2017 | 17 | 0.210 |
Why?
| | Blood Transfusion | 1 | 2017 | 48 | 0.200 |
Why?
| | Nutritional Status | 1 | 2017 | 52 | 0.200 |
Why?
| | Probiotics | 1 | 2017 | 22 | 0.200 |
Why?
| | Time Factors | 2 | 2018 | 1614 | 0.200 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2017 | 62 | 0.200 |
Why?
| | Return to Work | 1 | 2016 | 25 | 0.200 |
Why?
| | Peer Group | 1 | 2017 | 46 | 0.200 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 43 | 0.200 |
Why?
| | Program Evaluation | 1 | 2017 | 137 | 0.190 |
Why?
| | Anemia | 1 | 2017 | 87 | 0.190 |
Why?
| | Bacteremia | 1 | 2017 | 109 | 0.190 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 32 | 0.190 |
Why?
| | DNA, Bacterial | 1 | 2016 | 51 | 0.190 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2016 | 46 | 0.190 |
Why?
| | Illinois | 1 | 2016 | 214 | 0.190 |
Why?
| | Phylogeny | 1 | 2016 | 77 | 0.190 |
Why?
| | Cost of Illness | 2 | 2013 | 49 | 0.190 |
Why?
| | Chondroitinases and Chondroitin Lyases | 1 | 2015 | 6 | 0.180 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2015 | 13 | 0.180 |
Why?
| | Feces | 1 | 2016 | 89 | 0.180 |
Why?
| | Interviews as Topic | 1 | 2015 | 123 | 0.180 |
Why?
| | Cost Savings | 1 | 2015 | 32 | 0.170 |
Why?
| | Age Factors | 1 | 2017 | 773 | 0.170 |
Why?
| | Retinopathy of Prematurity | 1 | 2014 | 8 | 0.170 |
Why?
| | Adolescent | 3 | 2017 | 2259 | 0.170 |
Why?
| | Diabetes Insipidus, Neurogenic | 1 | 2013 | 3 | 0.160 |
Why?
| | Enterovirus Infections | 1 | 2013 | 4 | 0.160 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2013 | 4 | 0.160 |
Why?
| | Meningoencephalitis | 1 | 2013 | 10 | 0.160 |
Why?
| | Postnatal Care | 1 | 2013 | 7 | 0.160 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 365 | 0.160 |
Why?
| | Feeding Methods | 1 | 2013 | 5 | 0.160 |
Why?
| | Pharmacopoeias as Topic | 1 | 2012 | 5 | 0.150 |
Why?
| | Propensity Score | 1 | 2013 | 42 | 0.150 |
Why?
| | Costs and Cost Analysis | 1 | 2013 | 34 | 0.150 |
Why?
| | Pulmonary Gas Exchange | 2 | 2003 | 7 | 0.150 |
Why?
| | Direct Service Costs | 1 | 2012 | 5 | 0.150 |
Why?
| | Cardiovascular Agents | 1 | 2012 | 24 | 0.150 |
Why?
| | Tidal Volume | 2 | 2003 | 9 | 0.150 |
Why?
| | Infant, Newborn, Diseases | 1 | 2012 | 14 | 0.150 |
Why?
| | Sudden Infant Death | 2 | 2003 | 33 | 0.150 |
Why?
| | Hospital Costs | 1 | 2013 | 65 | 0.150 |
Why?
| | Codon, Terminator | 1 | 2011 | 1 | 0.140 |
Why?
| | Toll-Like Receptor 5 | 1 | 2011 | 1 | 0.140 |
Why?
| | Pediatrics | 1 | 2012 | 50 | 0.140 |
Why?
| | Longitudinal Studies | 1 | 2016 | 1111 | 0.140 |
Why?
| | Heart Diseases | 1 | 2012 | 87 | 0.140 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2011 | 1 | 0.140 |
Why?
| | African Americans | 1 | 2016 | 610 | 0.130 |
Why?
| | Fluconazole | 1 | 2010 | 7 | 0.130 |
Why?
| | Young Adult | 4 | 2018 | 1772 | 0.130 |
Why?
| | Cultured Milk Products | 1 | 2009 | 2 | 0.130 |
Why?
| | Milk | 1 | 2009 | 8 | 0.130 |
Why?
| | Mycoses | 1 | 2010 | 20 | 0.120 |
Why?
| | Antibiotic Prophylaxis | 1 | 2010 | 33 | 0.120 |
Why?
| | Antifungal Agents | 1 | 2010 | 39 | 0.120 |
Why?
| | Pilot Projects | 3 | 2018 | 371 | 0.110 |
Why?
| | Diet | 1 | 2009 | 169 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 535 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 3 | 2017 | 402 | 0.100 |
Why?
| | Ventricular Pressure | 1 | 1996 | 4 | 0.100 |
Why?
| | Lidocaine | 1 | 1996 | 34 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2005 | 98 | 0.090 |
Why?
| | Anti-Arrhythmia Agents | 1 | 1996 | 89 | 0.090 |
Why?
| | Ion Channel Gating | 1 | 1996 | 200 | 0.080 |
Why?
| | Respiratory Mechanics | 1 | 2003 | 7 | 0.080 |
Why?
| | Blood Gas Analysis | 1 | 2003 | 9 | 0.080 |
Why?
| | Respiratory Function Tests | 1 | 2003 | 28 | 0.080 |
Why?
| | Face | 1 | 2003 | 16 | 0.080 |
Why?
| | Videotape Recording | 1 | 2003 | 49 | 0.080 |
Why?
| | Polysomnography | 1 | 2003 | 88 | 0.080 |
Why?
| | Child | 3 | 2017 | 1314 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2017 | 576 | 0.070 |
Why?
| | Animals | 4 | 2017 | 4707 | 0.070 |
Why?
| | Air | 1 | 2001 | 7 | 0.070 |
Why?
| | Methods | 1 | 2001 | 25 | 0.070 |
Why?
| | Environment | 1 | 2001 | 56 | 0.070 |
Why?
| | Lymphoproliferative Disorders | 1 | 2001 | 21 | 0.070 |
Why?
| | Organ Transplantation | 1 | 2001 | 31 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 145 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2001 | 120 | 0.060 |
Why?
| | Maternal Age | 1 | 2018 | 10 | 0.060 |
Why?
| | North Carolina | 1 | 2018 | 12 | 0.060 |
Why?
| | Income | 1 | 2018 | 49 | 0.060 |
Why?
| | Gene Frequency | 1 | 2017 | 82 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 176 | 0.050 |
Why?
| | Risk | 1 | 2017 | 204 | 0.050 |
Why?
| | Odds Ratio | 1 | 2017 | 272 | 0.050 |
Why?
| | Tissue Donors | 1 | 2016 | 54 | 0.050 |
Why?
| | Phenotype | 1 | 2017 | 319 | 0.050 |
Why?
| | Child, Preschool | 2 | 2013 | 711 | 0.050 |
Why?
| | Macrophage Activation | 1 | 2015 | 10 | 0.050 |
Why?
| | Biomedical Research | 1 | 2016 | 75 | 0.050 |
Why?
| | Biological Availability | 1 | 2015 | 24 | 0.050 |
Why?
| | Chondroitin Sulfate Proteoglycans | 1 | 2015 | 47 | 0.040 |
Why?
| | NF-kappa B | 1 | 2015 | 99 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2015 | 291 | 0.040 |
Why?
| | Cell Line | 1 | 2015 | 341 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 92 | 0.040 |
Why?
| | Morbidity | 1 | 2014 | 54 | 0.040 |
Why?
| | Enterovirus B, Human | 1 | 2013 | 2 | 0.040 |
Why?
| | Ampicillin | 1 | 2013 | 9 | 0.040 |
Why?
| | Gentamicins | 1 | 2013 | 15 | 0.040 |
Why?
| | Risk Assessment | 1 | 2017 | 664 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 118 | 0.040 |
Why?
| | Organizational Culture | 1 | 2013 | 19 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2001 | 894 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 210 | 0.040 |
Why?
| | Inflammation | 1 | 2015 | 284 | 0.040 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2011 | 1 | 0.040 |
Why?
| | Cardiology | 1 | 2012 | 76 | 0.030 |
Why?
| | Disease Management | 1 | 2012 | 110 | 0.030 |
Why?
| | Heterozygote | 1 | 2011 | 85 | 0.030 |
Why?
| | Toll-Like Receptors | 1 | 2011 | 26 | 0.030 |
Why?
| | Genetic Variation | 1 | 2011 | 106 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 161 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2013 | 179 | 0.030 |
Why?
| | Cholestasis | 1 | 2010 | 12 | 0.030 |
Why?
| | Colostrum | 1 | 2010 | 7 | 0.030 |
Why?
| | Candidiasis | 1 | 2010 | 14 | 0.030 |
Why?
| | Mice | 1 | 2015 | 1604 | 0.030 |
Why?
| | Signal Transduction | 1 | 2011 | 512 | 0.030 |
Why?
| | Prognosis | 1 | 2009 | 826 | 0.020 |
Why?
| | Chick Embryo | 1 | 1996 | 22 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 1996 | 17 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2011 | 1094 | 0.020 |
Why?
| | Sodium Channels | 1 | 1996 | 15 | 0.020 |
Why?
| | Verapamil | 1 | 1996 | 33 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 1996 | 37 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2010 | 3111 | 0.020 |
Why?
| | Lymphoma | 1 | 2001 | 55 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2001 | 247 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2001 | 292 | 0.010 |
Why?
|
|
Patel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|